SCYNEXIS, Inc.
P.O. Box 12878
Research Triangle Park
North Carolina
27709
United States
Tel: 919-544-8600
Fax: 919-544-8697
Website: http://www.scynexis.com/
Email: terry.marquardt@scynexis.com
330 articles about SCYNEXIS, Inc.
-
SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update
8/9/2018
Oral dose regimen of ibrexafungerp (formerly SCY-078) identified for Phase 3 VVC development; Phase 3 on track for initiation in the fourth quarter of 2018
-
Arc Bio launched its proprietary antimicrobial resistance (AMR) software. It is the first in what it expects to be a series of next-generation sequencing (NGS)-based products for pathogen detection.
-
The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078
7/18/2018
New WHO INN stem "-fungerp" signifies a novel class of antifungals Novel generic name highlights the unique attributes of SCY-078 and its potential to address significant unmet needs across multiple indications
-
SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis
7/10/2018
Clinically and mycologically effective and well-tolerated oral dose of SCY-078 identified for use in Phase 3 registration program.
-
FDA’s Approval of T2 Biosystems T2Bacteria Panel Underlines Importance of Sepsis Diagnosis and Tr...
7/10/2018
On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area. -
SCYNEXIS to Present SCY-078 Data at Three Scientific Meetings in June/July 2018
6/14/2018
20th International Symposium on Infections in the Immunocompromised Host (ICHS)
-
SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018
6/11/2018
SCYNEXIS, Inc. announced the presentation of data at American Society for Microbiology (ASM) Microbe 2018
-
SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology
6/6/2018
New study results demonstrate low risk of interactions between SCY-078 and drugs metabolized by CYP enzymes
-
SCYNEXIS to Participate in a Panel at the 2018 BIO International Convention
5/23/2018
SCYNEXIS, Inc. today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a panel at the 2018 BIO International Conference at the Boston Convention and Exhibition Center on Wednesday, June 6, 2018 from 4:15 - 5:15 p.m. ET.
-
SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update
5/8/2018
Enrollment complete in Phase 2b DOVE study in VVC; on-track for top-line data by July 2018
-
On May 1, the U.S. Food and Drug Administration (FDA) granted Scynexi’s oral formulation of SCY-078 to treat vulvovaginal candidiasis (VVC) and recurrent VVC both Qualified Infectious Diseases Product (QIDP) and Fast Track Designation.
-
SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
5/1/2018
QIDP provides five additional years of market exclusivity, and Fast Track expedites the regulatory path Enrollment completed in Phase 2b DOVE study in VVC; on-track for top-line data by July 2018 Initiation of Phase 3 registration program in VVC planned for the fourth quarter of 2018, with potential NDA filing in 2020
-
SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis
4/23/2018
SCYNEXIS, Inc. announced data presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 21-24, 2018, in Madrid, Spain.
-
SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update
3/13/2018
SCYNEXIS, Inc. reported financial results for the year ended December 31, 2017, and provided an update on recent operational and clinical developments.
-
SCYNEXIS Announces Pricing of $30.0 Million Public Offering of Common Stock and Warrants
3/6/2018
SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten public offering of common stock and warrants.
-
SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018
2/1/2018
These results further confirm in vitro data that demonstrated the synergistic and additive activity of SCY-078 in combination with ISA against Aspergillus spp.
-
SCYNEXIS Provides Corporate and SCY-078 Pipeline Update
1/5/2018
SCYNEXIS today provided a corporate update, including recent pipeline developments and anticipated milestones in 2018, for its lead antifungal candidate, SCT-078.
-
SCYNEXIS Inc. to Participate in Upcoming Investor Conferences
11/28/2017
SCYNEXIS today announced that the Company will participate in two upcoming investor conferences.
-
SCYNEXIS Appoints Scott Sukenick as General Counsel
11/17/2017
Mr. Sukenick will be responsible for leading the Company's corporate strategic and tactical legal initiatives, including intellectual property and compliance.
-
SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update
11/8/2017
SCYNEXIS today reported financial results for the quarter ended September 30, 2017, and provided an update on recent operational and clinical developments.